 Sure. I'm Christopher Wood. I am a urologist. I work at MD Anderson Cancer Center down in Houston, Texas. We're one of the leading centers in terms of institutions treating patients with kidney cancer. I think that there's a lot for patients to learn from this. I think first of all patients should learn that there's hope. There's a lot of research going on in kidney cancer nowadays and a lot of that's being presented at this meeting. It's quite exciting times. I think also patients will glean from this what the appropriate care they should receive for a given stage of disease. In the session that I was a part of today, we learned about the importance of managing locally advanced kidney cancer. Patients should realize that even though these cases sometimes are complex, they're still very treatable. They would learn about the importance of lymph node dissection and management of IVC thrombus and things like that. So there's a lot of information to be gleaned from this conference for patients. I think first and foremost experience clearly matters and that's shown in the literature. So one of the questions that I would ask if I were a patient of a surgeon contemplating doing surgery on me is how many of these have you done? The literature is replete with numerous studies that show that the more volume a center has, the better their outcomes. So that's a critical question. And I think that the patient should also get an idea of what the overall plan is. It's important to particularly in patients with advanced disease that there is a interaction between the surgeon and the medical oncologist. Surgery shouldn't be done in a vacuum. Chemotherapy or targeted therapy shouldn't be done in a vacuum and there should definitely be an interplay between those two entities to show patients what the long term goals of their therapy are. Make sure that the left arm and the right arm are talking to one another so that the overall plan is to the patient's benefit.